Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
MORRISTOWN, N.J., May 01, 2018 -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today that the Company will report financial results for the first quarter ended March 31, 2018, after the market close on Thursday, May 10, 2018. Pernix management will also host a conference call at 4:30pm Eastern Time to discuss the results.
| Date: | Thursday, May 10 | ||||||||
| Time: | 4:30 PM ET | ||||||||
| Toll free (U.S.): | 888-394-8218 | ||||||||
| International: | 323-701-0225 | ||||||||
| Conference ID: | 7026871 | ||||||||
| Webcast: | http://public.viavid.com/index.php?id=129150 | ||||||||
About Pernix Therapeutics
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company is currently focused on the therapeutic areas of Pain and Neurology, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its internal sales force and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.
To learn more about Pernix Therapeutics, visit www.pernixtx.com.
CONTACT
Investor Relations
Bob Yedid
LifeSci Advisors, LLC
[email protected]
